Indomethacin therapy in hydramnios.
OBJECTIVE
The use of indomethacin in treatment of hydramnios was evaluated.


METHODS
Twelve patients with symptomatic hydramnios were treated with indomethacin (2.2- 3.0 mg/kg body weight/day).


RESULTS
The treatment was started at a gestational age of 31.17-/+7.94 weeks and continued for 3.74-/+2.3 weeks. Eleven patients responded to the therapy both subjectively and objectively and pregnancies were prolonged by 4.6-/+3.1 weeks (range 0.1-10 weeks). Five women had term deliveries. Six patients had a favourable perinatal outcome. Four patients who had a known congenital anomaly in the foetus, delivered stillborn babies or had an early neonatal death. One patient who did not follow up after commencing therapy delivered a full-term stillbirth. One patient delivered within 1 day of starting therapy. Indomethacin therapy caused no maternal complications.


CONCLUSIONS
Indomethacin was effective in the management of hydramnios and preventing it's complications.
Abhyankar
S
S
Department of Obstetrics and Gynaecology, Seth G. S. Medical College and K. E. M. Hospital, Parel, Mumbai - 400 012, India.
Salvi
V S
VS
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D005865:Gestational Age; D006801:Humans; D007213:Indomethacin / Q000008:administration & dosage*; D006831:Polyhydramnios / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011247:Pregnancy; D011256:Pregnancy Outcome; D012720:Severity of Illness Index; D016896:Treatment Outcome; D016216:Ultrasonography, Prenatal / Q000379:methods
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007213:Indomethacin